Weekly Recap

Patients with Parkinson at Greater Risk for Dementia After DBS Implant, a Novel ALS Diagnostic Index, Preliminary IGNITE-DMD Trial Findings

ByNeurologyLive® Staff

February 16th 2019

Neurology News Network for the week of February 14, 2019.

SPRINT-MIND Trial Results, Alemtuzumab and Rituximab Safe for MS, CAP-1002 for Duchenne Muscular Dystrophy

ByNeurologyLive® Staff

February 2nd 2019

Neurology News Network for the week of February 2, 2019.

Ocrelizumab Compared to Other DMTs, Effects of Lemborexant on Next-Day Driving, BHV-3241 Gets FDA OK for Clinical Trial

ByNeurologyLive® Staff

January 26th 2019

Neurology News Network for the week of January 26, 2019.

AHS Statement on CGRP Inhibitors, NDA Submitted for Lemborexant, Dabigatran Assessed in Alzheimer

ByNeurologyLive® Staff

January 19th 2019

Neurology News Network for the week of January 19, 2019.

Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers Identified, Long-Term Perampanel Data

ByNeurologyLive® Staff

January 12th 2019

Neurology News Network for the week of January 12, 2019.

Solriamfetol PDUFA Date Pushed, Recognizing Parkinson Disease, Chronic Migraine Peer Exchange Program

ByNeurologyLive® Staff

January 5th 2019

Neurology News Network for the week of January 5, 2019.

Oxtellar XR Approved as Monotherapy, Pregnancy Safety Data for Betaseron, and Biologic Brain Changes in Migraine

ByNeurologyLive® Staff

December 22nd 2018

Neurology News Network for the week of December 22, 2018.

Zilucoplan for Mysathenia Gravis, AXS-05 for Agitation in Alzheimer, and Chronic Migraine Management

ByNeurologyLive® Staff

December 15th 2018

Neurology News Network for the week of December 15, 2018.

Fingolimod Issued a Safety Warning, an NDA for BHV-0223 for ALS, and Lifestyle Modifications for Patients with Migraine

ByNeurologyLive® Staff

December 8th 2018

Neurology News Network for the week of December 1, 2018.

Galcanezumab for Cluster Headache, a Link Between Carotid Webs and Stroke, Managing Migraine Patient Relationships

ByNeurologyLive® Staff

November 24th 2018

Neurology News Network for the week of November 24, 2018.

An FDA Warning Letter, the Amyloid Hypothesis and Alzheimer Disease, Adverse Events with Triptan Use

ByNeurologyLive® Staff

November 17th 2018

Neurology News Network for the week of November 17, 2018.

Confounding Outcomes in Alzheimer, AFib and Dementia Risk, Cognitive Issues in Epilepsy, and MRI Imaging

ByNeurologyLive® Staff

November 10th 2018

Neurology News Network for the week of November 10, 2018.

Sodium Oxybate Approved, ANAVEX 2-73 Shows Positive Results, Ubrogepant for Acute Migraine Care, and Stroke Risk with Migraine

ByNeurologyLive® Staff

November 3rd 2018

Neurology News Network for the week of November 3, 2018.

Novel Deep Brain Stimulation System, ITI-214 Safe for Parkinson Disease, Elizabeth Ross on the Field's Progress

ByNeurologyLive® Staff

October 27th 2018

Neurology News Network for the week of Oct. 27, 2018.

New Alzheimer Association AUC, Patisiran Findings from AANEM, Evobrutinib findings from ECTRIMS

ByNeurologyLive® Staff

October 20th 2018

Neurology News Network for the week of October 20, 2018.

Siponimod NDA Accepted, New Appropriate Use Criteria for Alzheimer Disease Diagnosis, Disease-Modifying Therapy

ByNeurologyLive® Staff

October 13th 2018

Neurology News Network for the week of Oct. 12, 2018.

Never Events Common in Parkinson, Donepezil Fails to Prevent Psychosis, Helping Patients Live Well

ByNeurologyLive® Staff

October 6th 2018

Neurology News Network for the week of October 6, 2018.

Galcanezumab Approved, Pimavanserin Safety Confirmed, Treating Augmentation in RLS, Genetics in Alzheimer

ByNeurologyLive® Staff

September 29th 2018

Neurology News Network for the week of September 28, 2018.

FDA Approves Fremanezumab, Behavioral Activation Therapy for MCI, Choosing DMTs for MS

ByNeurologyLive® Staff

September 22nd 2018

Neurology News Network for the week of September 22, 2018.

XEN496 for KCNQ2 Epileptic Encephalopathy, the State of Acute Stroke Care, and Ocrelizumab's Success

ByNeurologyLive® Staff

September 15th 2018

Neurology News Network for the week of September 15, 2018.

Weekly Recap

Patients with Parkinson at Greater Risk for Dementia After DBS Implant, a Novel ALS Diagnostic Index, Preliminary IGNITE-DMD Trial Findings

SPRINT-MIND Trial Results, Alemtuzumab and Rituximab Safe for MS, CAP-1002 for Duchenne Muscular Dystrophy

Ocrelizumab Compared to Other DMTs, Effects of Lemborexant on Next-Day Driving, BHV-3241 Gets FDA OK for Clinical Trial

AHS Statement on CGRP Inhibitors, NDA Submitted for Lemborexant, Dabigatran Assessed in Alzheimer

Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers Identified, Long-Term Perampanel Data

Solriamfetol PDUFA Date Pushed, Recognizing Parkinson Disease, Chronic Migraine Peer Exchange Program

Oxtellar XR Approved as Monotherapy, Pregnancy Safety Data for Betaseron, and Biologic Brain Changes in Migraine

Zilucoplan for Mysathenia Gravis, AXS-05 for Agitation in Alzheimer, and Chronic Migraine Management

Fingolimod Issued a Safety Warning, an NDA for BHV-0223 for ALS, and Lifestyle Modifications for Patients with Migraine

Galcanezumab for Cluster Headache, a Link Between Carotid Webs and Stroke, Managing Migraine Patient Relationships

An FDA Warning Letter, the Amyloid Hypothesis and Alzheimer Disease, Adverse Events with Triptan Use

Confounding Outcomes in Alzheimer, AFib and Dementia Risk, Cognitive Issues in Epilepsy, and MRI Imaging

Sodium Oxybate Approved, ANAVEX 2-73 Shows Positive Results, Ubrogepant for Acute Migraine Care, and Stroke Risk with Migraine

Novel Deep Brain Stimulation System, ITI-214 Safe for Parkinson Disease, Elizabeth Ross on the Field's Progress

New Alzheimer Association AUC, Patisiran Findings from AANEM, Evobrutinib findings from ECTRIMS

Siponimod NDA Accepted, New Appropriate Use Criteria for Alzheimer Disease Diagnosis, Disease-Modifying Therapy

Never Events Common in Parkinson, Donepezil Fails to Prevent Psychosis, Helping Patients Live Well

Galcanezumab Approved, Pimavanserin Safety Confirmed, Treating Augmentation in RLS, Genetics in Alzheimer

FDA Approves Fremanezumab, Behavioral Activation Therapy for MCI, Choosing DMTs for MS

XEN496 for KCNQ2 Epileptic Encephalopathy, the State of Acute Stroke Care, and Ocrelizumab's Success

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency

New Phase 3 Study to Evaluate Remibrutinib in Generalized Myasthenia Gravis Treatment

Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS

New Study to Assess Complement Inhibitor Iptacopan in Generalized Myasthenia Gravis

Early-Stage Study to Test CD19 CAR T-Cell Therapy YTB323 in Myasthenia Gravis